TY - JOUR
T1 - A new chemotherapy regimen for treatment of hodgkin's disease associated with minimal genotoxicity
AU - Liang, Jan C.
AU - Bailey, Nell M.
AU - Gabriel, Gloria J.
AU - Kattan, Michael W.
AU - Wang, Rui Yu
AU - Hagemeister, Fredrick B.
AU - Cabanillas, Fernando F.
AU - Fuller, Lillian M.
N1 - Funding Information:
This work was supported in part by NIH Grant R01-CA43585 awarded to J. C. L. by the National Cancer Institute, National Institutes of Health.
PY - 1993
Y1 - 1993
N2 - Recently, the combination chemotherapy Novantrone, Oncovin, Velban, Prednisone [NOVP] was developed by The University of Texas M. D. Anderson Cancer Center for treatment of Hodgkin's disease [HD]. Preliminary clinical results show that NOVP is as effective as the traditional Mechlorethamine, Oncovin, Procarbazine, Prednisone [MOPP] regimen in achieving remission, but with fewer side-effects. To determine if NOVP is genotoxic, we studied the induction of chromosome breaks and sister chromatid exchanges [SCEs] in lymphocytes of 42 HD patients both before and during NOVP treatment. Furthermore, in vitro bleomycin treatment was used to unmask potential single-stranded DNA breaks inducted by the therapy. Our results showed that NOVP did not cause elevated levels of chromosome or single-stranded DNA breaks, or SCEs. These results together with previous findings that NOVP caused minimal acute and gonadal toxicities suggest that NOVP is less toxic than MOPP. Therefore, this new regimen shows promise as an effective and minimally toxic regimen for treatment of HD.
AB - Recently, the combination chemotherapy Novantrone, Oncovin, Velban, Prednisone [NOVP] was developed by The University of Texas M. D. Anderson Cancer Center for treatment of Hodgkin's disease [HD]. Preliminary clinical results show that NOVP is as effective as the traditional Mechlorethamine, Oncovin, Procarbazine, Prednisone [MOPP] regimen in achieving remission, but with fewer side-effects. To determine if NOVP is genotoxic, we studied the induction of chromosome breaks and sister chromatid exchanges [SCEs] in lymphocytes of 42 HD patients both before and during NOVP treatment. Furthermore, in vitro bleomycin treatment was used to unmask potential single-stranded DNA breaks inducted by the therapy. Our results showed that NOVP did not cause elevated levels of chromosome or single-stranded DNA breaks, or SCEs. These results together with previous findings that NOVP caused minimal acute and gonadal toxicities suggest that NOVP is less toxic than MOPP. Therefore, this new regimen shows promise as an effective and minimally toxic regimen for treatment of HD.
KW - Chemotherapy regimen
KW - Hodgkin's disease
KW - Minimal genotoxicity
UR - http://www.scopus.com/inward/record.url?scp=0027250158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027250158&partnerID=8YFLogxK
U2 - 10.3109/10428199309145757
DO - 10.3109/10428199309145757
M3 - Article
C2 - 7687918
AN - SCOPUS:0027250158
SN - 1042-8194
VL - 9
SP - 503
EP - 508
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -